Mayne Pharma share price on watch as earnings slump 27%

The Mayne Pharma Group Ltd (ASX: MYX) share price is one to watch this morning after reporting a mixed full year result to the market.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mayne Pharma Group Ltd (ASX: MYX) share price is one to watch this morning after reporting its latest full-year results.

Why is the Mayne Pharma share price on watch?

The Aussie pharma group reported revenue down 13% on FY19 to $457.0 million for the year ended 30 June 2020 (FY20).

Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) fell 27% to $95.3 million.

That saw Mayne Pharma reported a net loss after tax of $92.8 million. That was still a 66.7% improvement on FY19 figures even accounting for a $99.0 million impairment.

The pharma company reduced operating expenses by $16 million to optimise global infrastructure with a $15 million reduction in product development spend.

Net operating cash flow was up 16% on the first-half but down 6% for the year to $99.8 million.

On the operations side, there were some important updates that make the Mayne Pharma share price worth watching.

The company's generic products division stabilised in the second half. Sales were down 21% on FY19 to $253 million, however, gross profit was up 10% on the first half.

Metrics contracts services delivered solid revenue growth, up 15% on FY19 to $82.8 million. That saw gross profit climb 11% to $39.4 million with 5 commercial manufacturing clients now locked in.

The speciality brands division saw sales slump 14% to $78.8 million with gross profit down 18% to $65.4 million. The coronavirus pandemic hurt the business segment with fewer patient visits to doctors.

Positively, Mayne Pharma International sales were up 4% on FY19 to $42.4 million with gross profit flat at $11.0 million.

What did management have to say?

CEO Scott Richards noted the "unprecedented challenges" in dealing with COVID-19. The company focused on maintaining an uninterrupted supply of medicines and services during the second half.

That saw the half-year revenue flat on 1H FY20 numbers with net operating cash flow climbing 16% higher in the last 6 months.

The pharma group is looking to restructure its cost base, rationalise its generic portfolio and explore new areas of growth.

The Mayne Pharma share price will be one to watch in early trade as investors weigh up the latest strategy.

That includes completing the licensing of its NEXTSTELLIS product in the United States and Australia having received FDA filing acceptance for the novel contraceptive product.

The group also expects to commence a phase 3 trial in basal cell carcinoma nevus syndrome (BCCNS or Gorlin Syndrome) patients in FY21.

Outlook

There was no specific guidance provided by Mayne Pharma other than reiterating its near-term goals.

That included repositioning the company into "sustainable products, distribution channels and therapeutic areas."

Prior to the open, the Mayne Pharma share price was down 22.2% for the year versus an 8.5% decline in the S&P/ASX 200 Index (ASX: XJO).

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Market News

Broker gives its verdict on BHP shares

Let's see what Bell Potter is saying about the Big Australian.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Woman holding gold bar and cheering.
Gold

Why Macquarie expects this surging ASX 200 gold stock could leap another 40%

Macquarie forecasts another year of strong outperformance from this fast-rising ASX 200 gold miner.

Read more »

A young woman looks at here phone as she strides out in an airport dragging her wheelie bag behind her and smiling widely.
Broker Notes

Macquarie tips 15% upside for this ASX 200 industrials stock

Is this transportation business preparing for take-off?

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why 29Metals, Atlas Arteria, DroneShield, and Yancoal shares are falling today

Let's see why these shares are ending the week in the red.

Read more »